We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+25.11%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.83B
AUM Growth
+$194M
Cap. Flow
-$79.7M
Cap. Flow %
-4.36%
Top 10 Hldgs %
49.54%
Holding
75
New
12
Increased
19
Reduced
26
Closed
13

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$49.3M
2
AZN icon
AstraZeneca
AZN
+$40.1M
3
AXSM icon
Axsome Therapeutics
AXSM
+$33.8M
4
GKOS icon
Glaukos
GKOS
+$28.7M
5
UTHR icon
United Therapeutics
UTHR
+$24.3M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$75.6M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$31.5M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$29.6M
4
QURE icon
uniQure
QURE
+$25.8M
5
INSM icon
Insmed
INSM
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 89.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$22.5M 1.23%
473,625
-75,163
-14% -$3.64M
APGE icon
27
Apogee Therapeutics
APGE
$10.2B
$22.5M 1.23%
565,417
+489,237
+642% +$18.7M
EXAS
28
DELISTED
Exact Sciences
EXAS
$20M 1.09%
365,000
+156,700
+75% +$7.83M
IMTX icon
29
Immatics
IMTX
$1.24B
$19M 1.04%
2,227,837
-12,691
-0.6% -$78.2K
SMMT icon
30
CALL
Summit Therapeutics
SMMT
$10.9B
$18.6M 1.02%
900,000
+200,000
+29% +$4.85M
PHVS icon
31
Pharvaris
PHVS
$2.39B
$18.5M 1.01%
739,876
+154,344
+26% +$3.42M
SUPN icon
32
Supernus Pharmaceuticals
SUPN
$2.68B
$18M 0.99%
377,066
-422,187
-53% -$17M
QURE icon
33
CALL
uniQure
QURE
$2.68B
$17.5M 0.96%
+300,000
New +$5.45M
RCUS icon
34
Arcus Biosciences
RCUS
$3.57B
$16.6M 0.91%
1,222,263
+6,247
+0.5% +$65K
MRUS
35
DELISTED
Merus
MRUS
$15.7M 0.86%
166,729
-237,833
-59% -$15.5M
INSM icon
36
Insmed
INSM
$23.2B
$15M 0.82%
104,339
-209,584
-67% -$25.7M
INBX icon
37
Inhibrx
INBX
$1.2B
$14.8M 0.81%
440,092
-268,586
-38% -$6.61M
BIOA
38
BioAge Labs
BIOA
$968M
$13.5M 0.74%
2,293,788
-11,113
-0.5% -$52K
CELC icon
39
Celcuity
CELC
$4.03B
$12.5M 0.68%
+253,375
New +$10.1M
DYN icon
40
Dyne Therapeutics
DYN
$4.04B
$12.5M 0.68%
985,828
+370,963
+60% +$4.23M
PTCT icon
41
PTC Therapeutics
PTCT
$6.37B
$11.5M 0.63%
186,932
-189,007
-50% -$9.84M
GEHC icon
42
GE HealthCare
GEHC
$27.6B
$11.3M 0.62%
+151,085
New +$11.3M
SLNO
43
DELISTED
Soleno Therapeutics
SLNO
$11.2M 0.61%
166,281
-248,938
-60% -$18.5M
PRAX icon
44
Praxis Precision Medicines
PRAX
$9.07B
$9.16M 0.5%
172,833
+157,116
+1,000% +$7.62M
SVRA icon
45
Savara
SVRA
$1.13B
$8.67M 0.47%
2,427,724
-29,628
-1% -$87.6K
EWTX icon
46
Edgewise Therapeutics
EWTX
$4.39B
$8.44M 0.46%
520,240
-196,633
-27% -$2.79M
QURE icon
47
uniQure
QURE
$2.68B
$7.99M 0.44%
136,862
-1,421,494
-91% -$25.8M
ANAB icon
48
AnaptysBio
ANAB
$1.6B
$7.79M 0.43%
254,268
-778,094
-75% -$17.9M
CMPX icon
49
Compass Therapeutics
CMPX
$373M
$7.1M 0.39%
+2,028,886
New +$6.41M
NKTR icon
50
Nektar Therapeutics
NKTR
$2.39B
$6.74M 0.37%
+118,419
New +$3.92M
1
2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2025 Portfolio in Review

As of Q3 2025, Sofinnova Investments held 75 positions worth $1.83B, up 12% from $1.64B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sofinnova Investments withdrew a net $79.7M in Q3 2025, closing 13 positions and reducing 26 holdings. Its most notable exit was Eli Lilly, an estimated $75.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Vertex Pharmaceuticals worth $46.2M.

  • Sofinnova Investments's largest Q3 2025 buy was Vertex Pharmaceuticals: 117,875 shares worth $46.2M.
  • Sofinnova Investments added most to AstraZeneca in Q3 2025, an estimated $40.1M increase.
  • Sofinnova Investments's biggest Q3 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $31.5M.
  • Sofinnova Investments fully exited Eli Lilly in Q3 2025, selling an estimated $75.6M.
  • Sofinnova Investments's ten largest holdings make up 50% of its $1.83B portfolio in Q3 2025.
  • Sofinnova Investments opened 12 new positions and closed 13 in Q3 2025.
  • Sofinnova Investments's portfolio value rose 12% quarter-over-quarter to $1.83B.

Based on Sofinnova Investments's 13F filing for Q3 2025, filed 14 Nov 2025.